# US 2013/0157268 A1 · Phosphatidylinositol phosphate kinase type 1 gamma splice variants as biomarkers and drug targets for epithelial cancers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0157268 A1
- Document ID: US20130157268A1
- Status: Published application
- Kind: A1
- Application number: 13/690,903
- Filed: 2012-11-30
- Published: 2013-06-20
- Earliest claimed: 2007-10-02
- Assignees: Wisconsin Alumni Research Foundation
- Inventors: Richard A. Anderson; Nicholas J. Schill
- Web page: https://patentgrep.com/patent/US20130157268A1

## CPC

- C12N 9/1229: {Phosphotransferases with a phosphate group as acceptor (2.7.4)}
- C12N 9/1205: {Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases}
- C12Q 1/485: {involving kinase}
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- G01N 33/57515: of the breast
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/136: Screening for pharmacological compounds
- C12Q 2600/158: Expression markers
- G01N 2500/00: Screening for compounds of potential therapeutic value
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates generally to the field of phosphatidylinositol based signaling pathways, and more specifically to the use of novel members of these pathways for disease prognosis and treatment. In some aspects, the present invention relates to the use of novel splice variants of type I phosphatidylinositol phosphate kinase γ, named PIPKIγ 700 and PIPKIγ 707, to determine breast cancer and breast cancer prognosis.

## Claims

### Claim at position 1

-35. (canceled)

### Claim 36

An isolated polynucleotide encoding a polypeptide having lipid kinase activity, wherein the polynucleotide comprises a sequence selected from the group consisting of:
a) a polynucleotide sequence encoding an amino acid sequence having at least about 95% sequence identity to SEQ ID NO: 4;
b) a polynucleotide sequence comprising SEQ ID NO: 2;
c) a polynucleotide sequence which is fully complementary to the polynucleotides of (a) or (b).

### Claim 37 (depends on 36)

An expression vector comprising the polynucleotide of claim 36.

### Claim 38 (depends on 37)

An isolated host cell comprising the expression vector of claim 37.

### Claim 39 (depends on 36)

A method of producing a polypeptide encoded by a polynucleotide selected from the group consisting of the polynucleotide of claim 36(a)-36(c), the method comprising:
culturing a cell under conditions suitable for expression of the polypeptide,
wherein the cell is transformed with the polynucleotide, and wherein the polynucleotide comprises a promoter sequence operably linked to the polynucleotide.

### Claim 40

A method for prognostic evaluation of a patient comprising:
a) detecting a nucleic acid molecule comprising SEQ ID NO: 2 in a tissue sample from a patient having, suspected of having, or at risk of developing breast cancer;
b) comparing the results of step (a) with an amount of the same sequence detected in a control sample; and
c) evaluating the prognosis of the patient based on the comparison of step (b), wherein a lower amount of the detected sequence compared to the amount detected in the control sample indicates a better prognosis, and wherein an equal or higher amount of the detected sequence compared to the amount detected in the control sample indicates a poor prognosis.

### Claim 41 (depends on 40)

The method of claim 40, wherein the patient sample comprises a breast tissue sample.

### Claim 42 (depends on 40)

The method of claim 40, wherein the detecting step comprises a nucleic acid hybridization step.

### Claim 43 (depends on 40)

The method of claim 40, further comprising: detecting a nucleic acid molecule encoding one or more breast cancer markers in the patient sample, wherein the marker is selected from the group consisting of: HER-1, HER-2 and a combination thereof.

### Claim 44 (depends on 43)

The method of claim 43, further comprising:
d) determining the amount of HER-2 nucleic acid present in the sample;
e) comparing the results of step (d) with the amount of the HER-2 nucleic acid in a control sample; and
f) evaluating the prognosis of the patient based on the comparison in steps (b) and (e), wherein a higher level of HER-2, and an equal or higher level of the detected sequence in the patient sample compared to the amounts detected in the control sample indicates a poor prognosis.

### Claim 45 (depends on 40)

The method of claim 40, wherein the detecting step comprises amplification of a nucleic acid molecule comprising SEQ ID NO: 2 or a fragment thereof by polymerase chain reaction (PCR).

### Claim 46 (depends on 45)

The method of claim 45, wherein the PCR comprises use of an oligonucleotide comprising at least 10 contiguous nucleotides of SEQ ID NO:2 or a nucleic acid complementary to at least 10 contiguous nucleic acids of SEQ ID NO:2.

### Claim 47 (depends on 45)

The method of claim 45, wherein the PCR comprises use of the oligonucleotide 5′-ATGGAGCTGGAGGTACCGGA-3′ (SEQ ID NO: 13).

### Claim 48 (depends on 40)

The method of claim 40, wherein the PCR comprises use of the oligonucleotide 5′-TTACCCAAAGCCCTTCTGGAAA-3′ (SEQ ID NO: 14).

### Claim 49

A method for identifying an agent that modulates the activity of phosphatidylinositol phosphate kinase gamma 707 (PIPKIγ 707) comprising:
a) contacting the PIPKIγ 707 with the agent in the presence of LMO4; and
b) determining whether the agent modulates the activity or localization of LMO4 as compared to a control, wherein a change in the activity or localization of LMO4 as compared to the control is indicative of the agent modulating PIPKIγ 707 activity.

### Claim 50 (depends on 36)

A kit comprising the nucleic acid of claim 36.
